Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents

Federico Cappuzzo • 11 Apr 2018
ELCC 2018
Lung Cancer Non-Small Cell Lung Cancer Alectinib Osimertinib Pembrolizumab

In this interview, Federico Cappuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of non-small cell lung cancer (NSCLC) from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland. Dr Cappuzzo focuses on immunotherapy and targeted agents, and emphasizes the continued importance of defining the biological characteristics of NSCLC, particularly PD-L1 expression.

More from Federico Cappuzzo

1:25
Current treatment recommendations and future directions for EGFR-mutant NSCLC
Federico Cappuzzo • 7 Aug 2022
1:06
FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC
Federico Cappuzzo • 7 Aug 2022
1:18
MRD status in lung cancer
Federico Cappuzzo • 7 Aug 2022
1:06
METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis
Federico Cappuzzo • 7 Aug 2022

Related Videos

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals